CRN01941
Neuroendocrine Tumors
Phase 1Discovery/Preclinical
Key Facts
Indication
Neuroendocrine Tumors
Phase
Phase 1
Status
Discovery/Preclinical
Company
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is building a premier endocrine-focused biopharma company by developing oral small-molecule drugs targeting G-protein coupled receptors (GPCRs). Its lead candidate, paltusotine, is in late-stage development for acromegaly and neuroendocrine tumors, positioning the company for near-term commercialization. The strategy leverages a proprietary platform and deep scientific expertise to address significant unmet needs in endocrinology, a field ripe for innovation.
View full company profileTherapeutic Areas
Other Neuroendocrine Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| LNTH-2501/EVG-001 (Ga-68 edotreotide) | Lantheus Medical Imaging | Regulatory Filing |
| Oncology Focus (Neuroendocrine Tumors) | Curium Pharma | Not Specified |
| Lutathera® | Novartis | Approved / Phase III |
| Zanzalintinib (XL092) | Exelixis | Phase 3 |
| LNC1010 / LNC1014 | Lantheus Holdings | Phase 1 |